Navigation Links
Thalidomide Improves Outcomes for Older Myeloma Patients
Date:10/5/2007

Adding the drug to standard chemo boosted survival, study found

FRIDAY, Oct. 5 (HealthDay News) -- Elderly patients with multiple myeloma live longer when thalidomide is added to standard combination chemotherapy treatment, a new study finds.

The finding could be the first real treatment advance for these types of patients in decades, the researchers said.

Standard chemotherapy for elderly patients involves two drugs, melphalan plus prednisone, explained a French team who are publishing their findings in this week's issue of The Lancet medical journal.

The study included 447 previously untreated patients, ages 65 to 75, divided into three groups: 196 received melphalan and prednisone (MP); 125 received MP plus thalidomide (MPT); and 126 received reduced-intensity stem cell transplantation using melphalan (MEL100).

Median survival times were: 33.2 months in the MP group; 51.6 months in the MPT group; and 38.8 in the MEL100 group.

MPT patients were 41 percent less likely to die than MP patients and 31 percent less likely to die than MEL100 patients.

"Our study has shown that the addition of thalidomide to standard melphalan and prednisone significantly extended survival for elderly patients with previously untreated multiple myeloma," wrote a team led by Dr. Thierry Facon, of the Centre Hospitalier Universitaire de Lille. "We noted that the MPT regimen was better than the MP regimen in terms of response, including complete response, overall survival, and progression-free survival."

The researchers concluded that the results "provide strong evidence to suggest that the MPT combination, should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma. After 40 years of unsuccessful attempts to find a more effective treatment than the standard MP, the MPT combination opens an era of progress for elderly patients with the disease."

Two experts who weren't involved in the study agree. In an accompanying Lancet Comment, Dr. Antonio Palumbo and Dr. Mario Boccadoro wrote that "we now have extensive evidence to support the introduction of MPT as the standard of care for elderly patients with multiple myeloma."

More information

The American Cancer Society outlines treatment options for multiple myeloma.



-- Robert Preidt



SOURCE: The Lancet, news release, Oct. 5, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Thalidomide may stage a comeback
2. Thalidomide is the new approved drug for treating multiple cancers
3. Thalidomide for Tumor Treatment
4. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
5. Collagen improves voice quality in Parkinsonism
6. Breakfast improves memory
7. A new hearing device improves hearing
8. Hormone replacement therapy improves sexual function
9. New therapy improves quality of life for cancer
10. Adding contrast improves ultrasounds ability to detect prostate cancer
11. Switching drugs regularly improves HIV treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Southland ... line of classic American timber frame barn kits, which can be found on its ... inspired by historic American barn plans, and they highlight the craftsmanship of timber post ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke survivors ... sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics had ... with hemiplegia due to stroke. , Ekso Bionics has now received clearance from the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated a new ... This is the first time that Coolsculpting is being used for for more than ... to ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
Breaking Medicine Technology: